I have read about it a couple times in different articles, (I think they probably did because if you look at the timeframe of June/July 2015 TEVA was buying businesses 2015/or trying) The time I read the "offer" was in a story about TEVA (not OWCP) so I'd gues it was real but OWCP turned it down back in 2015.
Here was the Full Story (where OWCP was mention in a story about TEVA)
Teva Pharmaceutical Industries Ltd. (NYSE ADR: TEVA)
Teva Pharmaceutical Industries Ltd. (NYSE ADR: TEVA), out of Israel, manufactures, markets,
and distributes generic and specialty medicines worldwide. It is currently the world’s largest maker of
“generic” drugs.
Teva has signaled that it wants in on marijuana.
In July of 2015 Teva announced that it planned to acquire rival Allergan Generics for $40.5 billion dollars.
The move made perfect sense. Copaxone, Teva’s lead drug, is going off patent. That means generic
equivalents can be developed and sold, which will siphon away much of the $3.29 billion in revenue
Teva hoped to earn from Copaxone this year. Buying the generic drug maker would help offset some of
those losses.
Teva made another announcement last July that garnered less attention from the press.
The company revealed that it had made a bid to acquire the patents of another Israeli firm, One World
Cannabis (OWC).
One World Cannabis (a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTC:
OWCP)) conducts research and clinical trials into cannabis-based products to treat multiple myeloma,
psoriasis, fibromyalgia, PTSD, migraines, and other ailments.
Again, the move makes perfect sense. To offset declining revenue as its lead drug loses patent
protection,
Teva is looking to expand into medical marijuana.
OWC is still in the early stages of drug development, but it has produced some promising results.
According to online news site The Marker,
“OWC recently reported a study by the Sheba Medical
Center that showed a 60% reduction of malignant multiple myeloma cells within 24 hours of treatment
using the cannabis plant’s active ingredients.”
Nothing hurts a drug-makers top line as much as having its lead drug go off patent.
So expect more
and more Big Pharma players to begin exploring ways to leverage legal cannabis to replace some of
that revenue.
Teva Pharmaceutical has already made an “opening gambit.”
There are other signs that that the Israeli giant is taking a good look at medical marijuana
---So, you see the TEVA "offer" to buy OWCP PAtents in 2015 was first reported in "The Marker"
-Who is "The Marker" online news? See here:
TheMarker (Hebrew: דה-מרקר or דמרקר) is the arguably most influential business publication in Israel.
In 2006 and 2007 TheMarker and Rolnik won the 2 most important awards in marketing and business strategy for creating TheMarker, turning it into the leading brand in financial media and using an internet brand to launch a print newspaper
--- So it all looks Legit to me just on the DD of who reported it.
Here was the Full Story (where OWCP was mention in a story about TEVA)
Teva Pharmaceutical Industries Ltd. (NYSE ADR: TEVA)
Teva Pharmaceutical Industries Ltd. (NYSE ADR: TEVA), out of Israel, manufactures, markets,
and distributes generic and specialty medicines worldwide. It is currently the world’s largest maker of
“generic” drugs.
Teva has signaled that it wants in on marijuana.
In July of 2015 Teva announced that it planned to acquire rival Allergan Generics for $40.5 billion dollars.
The move made perfect sense. Copaxone, Teva’s lead drug, is going off patent. That means generic
equivalents can be developed and sold, which will siphon away much of the $3.29 billion in revenue
Teva hoped to earn from Copaxone this year. Buying the generic drug maker would help offset some of
those losses.
Teva made another announcement last July that garnered less attention from the press.
The company revealed that it had made a bid to acquire the patents of another Israeli firm, One World
Cannabis (OWC).
One World Cannabis (a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTC:
OWCP)) conducts research and clinical trials into cannabis-based products to treat multiple myeloma,
psoriasis, fibromyalgia, PTSD, migraines, and other ailments.
Again, the move makes perfect sense. To offset declining revenue as its lead drug loses patent
protection,
Teva is looking to expand into medical marijuana.
OWC is still in the early stages of drug development, but it has produced some promising results.
According to online news site The Marker,
“OWC recently reported a study by the Sheba Medical
Center that showed a 60% reduction of malignant multiple myeloma cells within 24 hours of treatment
using the cannabis plant’s active ingredients.”
Nothing hurts a drug-makers top line as much as having its lead drug go off patent.
So expect more
and more Big Pharma players to begin exploring ways to leverage legal cannabis to replace some of
that revenue.
Teva Pharmaceutical has already made an “opening gambit.”
There are other signs that that the Israeli giant is taking a good look at medical marijuana
---So, you see the TEVA "offer" to buy OWCP PAtents in 2015 was first reported in "The Marker"
-Who is "The Marker" online news? See here:
TheMarker (Hebrew: דה-מרקר or דמרקר) is the arguably most influential business publication in Israel.
In 2006 and 2007 TheMarker and Rolnik won the 2 most important awards in marketing and business strategy for creating TheMarker, turning it into the leading brand in financial media and using an internet brand to launch a print newspaper
--- So it all looks Legit to me just on the DD of who reported it.
